Polo-like Kinases (PLKs) are a family of highly conserved serine/threonine protein kinases that are essential for a variety of biological functions, including cell division and mitosis checkpoint regulation. Five PLKs (PLK 1-5) play a variety of roles in DNA damage response, intra-S-phase and G2/M checkpoints, spindle formation, and centrosome dynamics in mammals.
PLKs are distinguished by their Polo-box domain, which mediates protein interactions. Depending on the biological context, they are also regulated by transcription, proteolysis, and phosphorylation. PLKs are now understood to function in differentiated cells and link cell division to developmental processes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V60036 | 3MB-PP1 | 956025-83-5 | 3MB-PP1 is a bulky purine analog that is a Polo-like kinase 1 (Plk1) inhibitor. |
|
V1573 | BI 2536 | 755038-02-9 | BI2536 (BI-2536; BI 2536) is a novel PLK1/BRD4 dual inhibitor with potential antitumor activity. |
|
V52314 | BTO-1 | 40647-02-7 | BTO-1 is a Polo-like kinase (Plk) inhibitor. |
|
V17894 | Centrinone | 1798871-30-3 | Centrinone (LCR263; LCR-263; LCR 263) is a novel and potent inhibitor of polo-like kinase 4 (PLK4)with potential antineoplastic activity. |
|
V17895 | Centrinone-B | 1798871-31-4 | Centrinone-B (LCR323; LCR-323; LCR 323) is a novel and reversible polo-like kinase 4 (PLK4) inhibitor with potential anticancer activity. |
|
V2427 | CFI-400437 HCl | 1247000-76-5 | (1E)-CFI-400437 diHCl is potent against PLK4 (IC50= 0.6 nM) and selective for other members of the PLK family (>10 μM). |
|
|
V51036 | CZS-241 | CZS-241 is a novel Polo-like Kinase (PLK) 4 inhibitor (IC50=2.6 nM). | |
|
V54801 | Dihydrobaicalein | 35683-17-1 | DiHydrobaicalein is a PLK1 inhibitor (antagonist) with IC50 of 6.3 μM. |
|
V1576 | GSK461364 | 929095-18-1 | GSK-461364 (GSK461364; GSK 461364)is a novel, potent, selective, reversible and ATP-competitive small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antitumor activity. |
|
V4918 | GW843682X | 660868-91-7 | GW843682X is a novel, potent, selective, ATP-competitive inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) with IC50s of 2.2 nM and 9.1 nM, respectively. |
|
V22224 | HMN-176 | 173529-10-7 | HMN-176 is an analogue of diphenylethylene that can inhibit mitosis and interfere with plk1, but has little effect on tubulin polymerization. |
|
V1577 | HMN-214 | 173529-46-9 | HMN-214 (HMN 214; HMN214), stilbene derivative, is a potent and orally bioactive prodrug of HMN-176, which alters the cellular spatial orientation of Plk1 (polo-like kinase-1). |
|
V1578 | MLN0905 | 1228960-69-7 | MLN0905 (MLN-0905; MLN 0905) is a novel, potent and selective small-molecule inhibitor of polo-like kinase-1 (PLK1) with potential antineoplastic activity. |
|
V1580 | NMS-P937 (NMS1286937; Onvansertib) | 1034616-18-6 | NMS-P937 (also know as NMS-P937;NMS1286937;NMS-P-937; NMS-P 937; Onvansertib) is an orally bioavailable, potent, selective, small-molecule Polo-like Kinase 1 (PLK1) inhibitor with potential antitumor activity. |
|
V2729 | Ocifisertib (CFI-400945) | 1338806-73-7 | CFI400945 is a potent, selective, and orally bioavailable PLK4 (polo-like kinase 4) inhibitor with IC50 value of 2.8 ±1.4 nM and potential antineoplastic activity. |
|
V55106 | PLK1-IN-2 | 2640254-52-8 | PLK1-IN-2 is a PLK1 kinase inhibitor (antagonist) with IC50 of 0.384 μM. |
|
V55107 | PLK1-IN-5 | 1001343-34-5 | PLK1-IN-5 is a potent PLK1 inhibitor (antagonist) with IC50 < 500 nM. |
|
V75966 | PLK1-IN-7 | 2938910-96-2 | PLK1-IN-7 (compound 30e) is a potent inhibitor of PLK1 with IC50 of 0.66 nM. |
|
V55108 | PLK4-IN-1 | 1247001-12-2 | PLK4-IN-1 (Example A6) is an inhibitor (blocker/antagonist) of PLK4 with IC50 of ≤ 0.1 μM. |
|
V55109 | PLK4-IN-3 | 1247001-86-0 | PLK4-IN-3 is the absolute configuration of PLK4-IN-1. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
